QR Code (код быстрого отклика)

Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database

Introduction: ALK–rearranged advanced NSCLC (aNSCLC) represents 4% of all NSCLCs, and multiple ALK-targeted therapies (ALK-inhibitors) are now available for use. Little is known about changes in treatment patterns, or how prognostic factors and sequence of therapy may impact overall survival in the...

Полное описание

Сохранить в:
Главные авторы: Grace Chazan, M.B.B.S., BSc, FRACP, Fanny Franchini, BSc, MSc, DPhil, Roma Shah, MPH, Marliese Alexander, BPharm (Hons), MPH, PhD, Ani John, PhD, Maarten IJzerman, BSc, MSc, PhD, Benjamin Solomon, M.B.B.S., PhD, FRACP
Формат: Artigo
Язык:Inglês
Опубликовано: Elsevier 2024-08-01
Серии:JTO Clinical and Research Reports
Предметы:
ALK+ lung cancer
Prognostic factors
Treatment sequence
Real-world
Online-ссылка:http://www.sciencedirect.com/science/article/pii/S2666364324000328
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы